Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chelerythrine is a benzophenanthridine alkaloid isolated from plants such as Chelidonium majus and species of Zanthoxylum. It is primarily known as a potent and selective inhibitor of protein kinase C (PKC), acting as a cell-permeable small molecule. In addition to PKC inhibition, chelerythrine antagonizes G-protein-coupled CB1 receptors and inhibits pro-survival proteins like BclXL by blocking their binding to Bak BH3 peptides. This leads to the induction of apoptosis in various cancer cell lines through disruption of calcium homeostasis and mitochondrial function. Chelerythrine also exhibits antibacterial activity by disrupting bacterial cell walls and membranes. Its biological activities include antitumor, anti-inflammatory, antidiabetic effects and it has been used experimentally for its ability to induce apoptosis in cancer cells[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chelerythrine.